Ratings DexCom, Inc. Sao Paulo

Equities

D1EX34

BRD1EXBDR004

Market Closed - Sao Paulo Other stock markets 12:56:32 2024-06-25 EDT			5-day change	1st Jan Change
12.07 ^BRL	+0.42%		-4.81%	-0.74%

06-26	Wall Street: up, on the edge, despite rates	CF
06-25	Out with AI, in with defensive stocks

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 67% by 2026.
The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The company returns high margins, thereby supporting business profitability.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 62.77 times its estimated earnings per share for the ongoing year.
The company's "enterprise value to sales" ratio is among the highest in the world.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The valuation of the company is particularly high given the cash flows generated by its activity.
The average consensus view of analysts covering the stock has deteriorated over the past four months.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
DEXCOM, INC.	-0.74%	45.09B	-
ABBOTT LABORATORIES	-5.60%	181B	C+
MEDTRONIC PLC	-4.45%	101B	C
BECTON, DICKINSON AND COMPANY	-4.15%	67.54B	A
CENCORA, INC.	+9.70%	44.37B	B-
HOYA CORPORATION	+5.36%	40.7B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+15.22%	29.85B	B
TERUMO CORPORATION	+10.26%	24.49B	A-
WEST PHARMACEUTICAL SERVICES, INC.	-6.46%	23.99B	A-
ZIMMER BIOMET HOLDINGS, INC.	-10.82%	22.33B	B

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes